Epivir and Sarcoidosis - a phase IV clinical study of FDA data

Summary:

Sarcoidosis is reported as a side effect among people who take Epivir (lamivudine), especially for people who are male, 30-39 old, have been taking the drug for 1 - 2 years also take Retrovir,.

The phase IV clinical study analyzes which people have Sarcoidosis when taking Epivir. It is created by eHealthMe based on reports of 16,823 people who have side effects when taking Epivir from the FDA, and is updated regularly.

What is Epivir?

Epivir has active ingredients of lamivudine. It is often used in hiv infection. eHealthMe is studying from 16,870 Epivir users. Check the latest studies of Epivir.

What is Sarcoidosis?

Sarcoidosis (an inflammatory disease that affects multiple organs in the body, but mostly the lungs and lymph glands) is found to be associated with 546 drugs and 611 conditions by eHealthMe. Check the latest studies of Sarcoidosis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

16,823 people reported to have side effects when taking Epivir.
Among them, 13 people (0.08%) have Sarcoidosis.

Among these 13 people:

How long have people been on Epivir when they have Sarcoidosis? *

What is the gender of people who have Sarcoidosis when taking Epivir? *

female: 15.38 %
male: 84.62 %

What is the age of people who have Sarcoidosis when taking Epivir? *

What are other drugs people take besides Epivir? *

What are other side effects people have besides Sarcoidosis? *

Immune Reconstitution Syndrome (immune recovery syndrome): 5 people, 38.46%
Lymph Follicular Hypertrophy (an increase in the size of the lymph node follicles): 3 people, 23.08%
Weakness: 3 people, 23.08%
Nausea (feeling of having an urge to vomit): 3 people, 23.08%
Cough: 3 people, 23.08%
Bone Disorder: 2 people, 15.38%
Nephritis Interstitial (a kidney condition characterized by swelling in between the kidney tubules): 2 people, 15.38%
Muscle Aches (muscle pain): 2 people, 15.38%
Fatigue (feeling of tiredness): 2 people, 15.38%
Dyspnea Exertional: 2 people, 15.38%

* Approximation only. Some reports may have incomplete information.

Do you take Epivir and have Sarcoidosis?

- Check whether Sarcoidosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Epivir:

Epivir (16,870 reports)

Sarcoidosis treatments and more:

Sarcoidosis (11,686 reports)

Browse all side effects of Epivir:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Sarcoidosis:

Sarcoidosis (546 drugs)

Browse all the conditions that are associated with Sarcoidosis:

Sarcoidosis (611 conditions)

Related publications that referenced our studies

?UPANI? KRMEK DU, BRAJKOVI? I, BEKI? D, KRNI? A, JURKOVI? P, PAVLOVI? T, "CALCIFIED DEEP VEIN THROMBOSIS IN A PATIENT WITH RECURRENT DEEP VEIN THROMBOSIS AND SARCOIDOSIS", Acta Medica Croatica, 2014 Mar .
Khedr YA, Khedr AH, "Sarcoidosis patient: an unexpected reaction to carbonic anhydrase enzyme inhibitor", BMJ case reports, 2013 Jul .
Kang SM, Baek JY, Hwangbo B, Kim HY, Lee GK, Lee HS, "A case of capecitabine-induced sarcoidosis", Tuberculosis and respiratory diseases, 2012 Mar .
?UPANI? KRMEK DU, BRAJKOVI? I, BEKI? D, KRNI? A, JURKOVI? P, PAVLOVI? T, "CALCIFIED DEEP VEIN THROMBOSIS IN A PATIENT WITH RECURRENT DEEP VEIN THROMBOSIS AND SARCOIDOSIS", Acta Medica Croatica, 2014 Mar .
Khedr YA, Khedr AH, "Sarcoidosis patient: an unexpected reaction to carbonic anhydrase enzyme inhibitor", BMJ case reports, 2013 Jul .
Kang SM, Baek JY, Hwangbo B, Kim HY, Lee GK, Lee HS, "A case of capecitabine-induced sarcoidosis", Tuberculosis and respiratory diseases, 2012 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on lamivudine (the active ingredients of Epivir) and Epivir (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.